• 1
    Koss LG. The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA 1989; 261: 73743.
  • 2
    Nanda K,McCrory DC,Myers ER,Bastian LA,Hasselblad V,Hickey JD,Matchar DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132: 81019.
  • 3
    Arbyn M,Sasieni P,Meijer CJ,Clavel C,Koliopoulos G,Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006; 24( Suppl 3): S7889.
  • 4
    Koliopoulos G,Arbyn M,Martin-Hirsch P,Kyrgiou M,Prendiville W,Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007; 104: 23246.
  • 5
    The Working group of IARC. IARC handbooks of cancer prevention: cervical cancer, vol. 10. Lyon: IARC Press, 2005.
  • 6
    Kotaniemi-Talonen L,Nieminen P,Anttila A,Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 2005; 93: 8627.
  • 7
    Cuzick J,Clavel C,Petry KU,Meijer CJ,Hoyer H,Ratnam S,Szarewski A,Birembaut P,Kulasingam S,Sasieni P,Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095101.
  • 8
    Anttila A,Hakama M,Kotaniemi-Talonen L,Nieminen P. Alternative technologies in cervical cancer screening: a randomised evaluation trial. BMC Public Health 2006; 6: 252.
  • 9
    Miettinen O,Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4: 21326.
  • 10
    Ronco G,Giorgi-Rossi P,Carozzi F,Dalla Palma P,Del Mistro A,De Marco L,De Lillo M,Naldoni C,Pierotti P,Rizzolo R,Segnan N,Schincaglia P, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 54755.
  • 11
    Ronco G,Segnan N,Giorgi-Rossi P,Zappa M,Casadei GP,Carozzi F,Dalla Palma P,Del Mistro A,Folicaldi S,Gillio-Tos A,Nardo G,Naldoni C, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 76574.
  • 12
    Kuhn L,Denny L,Pollack A,Lorincz A,Richart RM,Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000; 92: 81825.
  • 13
    Schiffman M,Herrero R,Hildesheim A,Sherman ME,Bratti M,Wacholder S,Alfaro M,Hutchinson M,Morales J,Greenberg MD,Lorincz AT. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000; 283: 8793.
  • 14
    Clavel C,Masure M,Bory JP,Putaud I,Mangeonjean C,Lorenzato M,Nazeyrollas P,Gabriel R,Quereux C,Birembaut P. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001; 84: 161623.
  • 15
    Kulmala SM,Syrjanen S,Shabalova I,Petrovichev N,Kozachenko V,Podistov J,Ivanchenko O,Zakharenko S,Nerovjna R,Kljukina L,Branovskaja M,Grunberga V, et al. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. J Clin Microbiol 2004; 42: 24705.
  • 16
    Szarewski A,Cadman L,Mallett S,Austin J,Londesborough P,Waller J,Wardle J,Altman DG,Cuzick J. Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting. J Med Screen 2007; 14: 3442.
  • 17
    Mayrand MH,Duarte-Franco E,Coutlee F,Rodrigues I,Walter SD,Ratnam S,Franco EL. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006; 119: 61523.
  • 18
    Viikki M,Pukkala E,Hakama M. Risk of cervical cancer after a negative Pap smear. J Med Screen 1999; 6: 1037.
  • 19
    Anttila A,Pukkala E,Soderman B,Kallio M,Nieminen P,Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963–1995: recent increase in cervical cancer incidence. Int J Cancer 1999; 83: 5965.
  • 20
    Leinonen M,Kotaniemi-Talonen L,Anttila A,Dyba T,Tarkkanen J,Nieminen P. Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland. Int J Cancer 2008; 123: 13449.
  • 21
    Castle PE,Lorincz AT,Mielzynska-Lohnas I,Scott DR,Glass AG,Sherman ME,Schussler JE,Schiffman M. Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J Clin Microbiol 2002; 40: 108890.
  • 22
    Hakama M. Trends in the incidence of cervical cancer in the Nordic countries. In: MagnusK, ed. Trends in cancer incidence. Washington: Hemisphere Publishing Corporation, 1982. 27992.
  • 23
    Kotaniemi-Talonen L,Anttila A,Malila N,Tarkkanen J,Laurila P,Hakama M,Nieminen P. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 2008; 44: 56571.